G2DR: A Genotype-First Framework for Genetics-Informed Target Prioritization and Drug Repurposing
Muhammad Muneeb, David B. Ascher · 2026
Read G2DR: A Genotype-First Framework for Genetics-Informed Target Prioritization and Drug Repurposing by Muhammad Muneeb, David B. Ascher (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/arxiv-2603-20346.txt.
Introduction
Muneeb and Ascher present G2DR, a framework that turns genetic signals into drug target leads. Human genetics can point to new therapies, but usable ranking tools remain scarce. Their method traces inherited variants through predicted gene expression and pathway tests. Network context, druggability, and drug-target evidence then shape the final ranks. In a migraine case study with 733 UK Biobank participants, results held up. Gene-level ROC-AUC reached 0.775 on held-out data. The authors stress the tool generates hypotheses, not clinical advice.
Catalog record
| CREATOR | Muhammad Muneeb, David B. Ascher |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 68991 |
| LICENSE | http://creativecommons.org/licenses/by/4.0/ |
| RIGHTS | CC BY |
| SOURCE | arXiv |
Source: https://arxiv.org/abs/2603.20346
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
G2DR: A Genotype-First Framework for Genetics-Informed Target Prioritization and Drug Repurposing Muhammad Muneeb, David B. Ascher Abstract Human genetics offers a promising route to therapeutic discovery, yet practical frameworks that translate genotype-derived signal into ranked target and drug hypotheses remain limited, particularly when matched disease transcriptomics are unavailable. Here, we present G2DR, a genotype-first computational prioritization framework that propagates inherited genetic variation through genetically predicted gene expression, multi-method gene-level testing, pathway enrichment, network context, druggability, and multi-source drug–target evidence integration to generate ranked hypotheses for downstream follow-up. In a migraine case study using 733 UK Biobank participants (53 cases and 680 controls) under stratified five-fold cross-validation, we imputed genetically regulated expression across seven transcriptome-weight resources and ranked genes using a reproducibility-aware discovery score derived exclusively from training and validation data, followed by a balanced integrated score for downstream target selection. In held-out evaluation, discovery-based prioritization generalized to unseen data, achieving a gene-level ROC-AUC of 0.775 and PR-AUC of 0.475 for recovery of test-significant genes, while retaining enrichment for curated migraine-associated biology. Mapping prioritized genes to compounds through Open Targets, DGIdb, and ChEMBL yielded candidate drug sets enriched for migraine-linked and literature-associated compounds relative to a global drug background, although recovery was strongest for broader mechanism-linked and off-label therapeutic space rather than migraine-specific approved therapies. Directionality filtering further separated broadly recovered compounds from those with stronger mechanistic compatibility. G2DR should therefore be interpreted as a modular computational prioritization framework for genetics-informed hypothesis generation and follow-up in genotype-first settings, not as a clinically actionable target-identification or drug-recommendation system. All prioritized genes and compounds require independent experimental, pharmacological, and clinical validation. Supplementary data are available at Briefings in Bioinformatics online. Muneeb et al . \ast ]Corresponding author: David B. Ascher, Email: [email protected] keywords drug repurposing, human genetics, TWAS, genetically predicted expression, target prioritization, translational bioinformatics † † journal: Briefings in Bioinformatics † † copyright-year: 2026 † † year: 2026 † † appnotes: Paper † † firstpage: 1 † † address: School of Chemistry and Molecular Biology, The University of Queensland, Queen Street, 4067, \state Queensland, Australia † † address: Computational Biology and Clinical Informatics, Baker Heart and Diabetes Institute, Commercial Road, 3004, \state Victoria, Australia † † corresponding: [ 1 Introduction Drug repurposing remains an attractive strategy for accelerating therapeutic development because existing compounds benefit from prior pharmacological, toxicological, and manufacturing knowledge ( 3 ; 48 ; 42 ). Over the past two decades, computational repurposing has expanded from expression-signature matching ( 34 ) and network medicine ( 27 ; 4 ; 38 ) to machine-learning and knowledge-graph approaches that integrate heterogeneous biomedical evidence at scale ( 26 ; 61 ). Yet many current pipelines depend on disease-specific transcriptomic profiles ( 55 ; 33 ), curated disease modules ( 4 ; 39 ), or historical drug–disease labels ( 48 ; 26 ), which can be limiting for newly studied phenotypes or for biobank settings where genotype and phenotype labels are available but disease-relevant molecular profiling is sparse or absent ( 56 ; 9 ; 48 ; 57 ). Human genetics provides a particularly attractive starting point for therapeutic prioritization because inherited variation is stable, scalable, and increasingly well characterized across large cohorts ( 56 ; 9 ). When measured expression is unavailable, genotype can be propagated through transcriptome imputation models to estimate genetically regulated expression ( 15 ; 22 ), offering an interpretable intermediate layer between variant-level signal and candidate genes ( 57 ). This strategy is appealing, but it also comes with important caveats: TWAS-style approaches prioritize genes associated with trait-linked regulatory signal, not necessarily causal effector genes ( 57 ), and inference remains sensitive to linkage disequilibrium, co-regulation, tissue context, ancestry, and model architecture ( 57 ; 5 ). These limitations argue for integrative frameworks that improve robustness and interpretability rather than relying on any single transcriptome-prediction resource or analytical test ( 57 ). A further motivation comes from therapeutic translation. Multiple studies have shown that targets supported by human genetics are more likely to succeed in clinical development ( 41 ; 31 ), making genetics-informed target selection an increasingly important component of drug discovery. However, the key translational challenge is not simply to detect associated genes, but to prioritize those with the strongest convergent support and then connect them to tractable pharmacological hypotheses in a transparent and reproducible manner. Here, we present G2DR (Figure 1 ), a genotype-first computational framework for genetics-informed target prioritization and drug repurposing hypothesis generation. G2DR integrates genetically predicted expression (Table 1 ) from multiple transcriptome-weight resources ( 15 ; 22 ; 57 ), multi-method gene-level testing, pathway enrichment, network context, structure- and knowledge-based druggability, and multi-source drug–target evidence ( 43 ; 14 ; 17 ; 18 ; 58 ) to generate ranked computational hypotheses for candidate targets and associated compounds, without requiring measured disease transcriptomics or supervised training on curated indication labels ( 48 ). Figure 1: Overview of the G2DR framework. Genotype and phenotype data from the migraine cohort were partitioned by stratified cross-validation and propagated through genotype-based transcriptome imputation across multiple expression-weight resources. Covariate-adjusted predicted expression values were tested using multiple differential-expression and association methods, and significant results from the training and validation splits were aggregated into a discovery set. Genes were then ranked using a composite score that integrated reproducibility, effect magnitude, and statistical confidence, followed by pathway, network, and druggability annotation to generate an integrated target-prioritization score. Top-ranked genes were mapped to candidate compounds through Open Targets, DGIdb, and ChEMBL, and the resulting drug lists were evaluated against curated migraine-associated drug references. Table 1: Expression weight models used for genotype-based gene expression prediction. Model Source Description Gene–Tissue Pairs MASHR https://zenodo.org/records/7551845 Multivariate adaptive shrinkage models for cross-population transcriptome prediction, designed to improve TWAS performance in underrepresented populations 2 686,241 (49 tissues) JTI https://zenodo.org/records/3842289 Joint-tissue imputation models that borrow information across tissues via shared genetic regulation, enabling both expression prediction and downstream causal inference 60 533,141 (49 tissues) CTIMP https://github.com/yiminghu/CTIMP Cross-tissue gene-expression imputation models trained with sparse group-LASSO to borrow information across GTEx tissues 28 404,450 (49 tissues) UTMOST https://zenodo.org/records/3842289 Cross-tissue transcriptome prediction models from the UTMOST framework, hosted alongside JTI models; treated as a separate model set in this study 28 340,104 (49 tissues) EpiXcan https://www.synapse.org/Synapse:syn52745052 Transcriptome imputation incorporating epigenomic annotations to weight SNP priors, improving prediction accuracy over standard elastic net 59 143,609 (14 tissues) FUSION http://gusevlab.org/projects/fusion/ Bayesian sparse linear mixed model and penalized regression framework for transcriptome-wide association studies 22 265,052 (48 tissues) TIGAR https://github.com/yanglab-emory/TIGAR Nonparametric Bayesian gene expression imputation tool supporting individual- and summary-level GWAS data for transcriptome-wide association studies 40 181,605 (49 tissues) We demonstrate the framework in migraine using UK Biobank data and evaluate performance at multiple levels, including held-out gene replication, enrichment for curated migraine biology, and recovery of migraine-linked drugs from prioritized targets. Framed explicitly as a computational prioritization engine for downstream experimental follow-up rather than a clinically actionable target-identification system, G2DR is best viewed as a modular proof-of-concept framework with clear room for further maturation. 2 Methods 2.1 Study Design and Cohort Assembly A total of 733 participants (53 cases and 680 controls) who reported migraine and recorded comorbid conditions, including hypertension, asthma, depression, osteoarthritis, hypercholesterolemia, irritable bowel syndrome, hypothyroidism, hay fever, and gastroesophageal